Migraine drug trial results boost Teva

Teva's Ajovy migraine treatment Photo: Company website
Teva's Ajovy migraine treatment Photo: Company website

The FOCUS Phase IIIb trial results published by 'The Lancet" demonstrate that Ajovy significantly relieves migraines.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) share price has been boosted by positive trial results for its Ajovy migraine treatment posted in the online edition of UK medical magazine "The Lancet." Teva''s share price is up 3% in premarket trading.

The Phase IIIb FOCUS study, which examined Ajovy (fremanezumab) versus placebo in 838 adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, found that Ajovy was superior versus placebo across all primary and secondary endpoints. Teva said that treatment resulted in statistically significant reductions in monthly average number of migraine days in participants who received either monthly or quarterly dosing with Ajovy during the study.

Teva Global Medical Lead for Migraine & Headache Joshua M. Cohen said, “Migraine can be debilitating for patients - and frustrating for those who have failed multiple preventive treatments. We continue our clinical trial efforts in the area of migraine research and we are very pleased with the FOCUS results. Fremanezumab shows promise for patients with migraine, and being published in the Lancet, a very prestigious medical journal, demonstrates the value of the clinical work being done at Teva to support and elevate the need for migraine education and treatment.”

Ajovy is already approved in the US and Europe for the preventive treatment of migraines in adults. The treatment had sales of $43 million in the first six months of 2019 and Teva expects sales of $110 million in the second half of the year. The newly approved drug is a key growth driver on which Teva is banking to help offset the fast falling sales of multiple sclerosis treatment Copaxone, whose patent has expired.

Published by Globes, Israel business news - en.globes.co.il - on August 21, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

Teva's Ajovy migraine treatment Photo: Company website
Teva's Ajovy migraine treatment Photo: Company website
Orit Strook  credit: Marc Israel Sellem/The Jerusalem Post Finance C'ttee approves NIS 300m coalition funds distribution

The money will mainly go to Religious Zionist party minister Orit Strook's Ministry of Settlements and National Missions.

Dangoor Academy  credit: British Embassy in Tel Aviv British Embassy showcases Israeli healthcare startups

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

NextVision Stabilized Systems  credit: Shlomi Yosef/Tali Bogdanovsky Next Vision shareholders make NIS 230m exit

A British hedge fund has bought a 2.5% stake in the stabilized cameras company.

Energean CEO Mathios Rigas at the Israel Business Conference   credit: Shlomi Yosef Energean's $1b gas fields sale at risk

The sale of the energy company's asset portfolio in Egypt, Italy and Croatia may fall through because of the buyer's difficulties with the Italian regulator.

Kela Technologies founders Jason Manne, Hamutal Meridor, Alon Dror and Omer Bar Ilan  credit:  Yosef Haim Alterman Defense tech co Kela raises $39m

In response to the events of October 7, Kela has developed a platform for rapid integration of commercial technologies into military systems.

Benjamin Netanyahu  credit: ‎Alex Kolomoisky, Yediot Aharonot Firing the Shin Bet chief: The hurdles

Prime Minister Benjamin Netanyahu says he has "lost trust" in Shin Bet head Ronen Bar. Will this be enough to overcome legal challenges to his dismissal?

Emiliano Calemzuk  credit: PR CEO and "investor group" buying out Reshet 13

CEO Emiliano Calemzuk and the other investors will hold 74% of the television channel, while Len Blavatnik’s Access Industries and WBD will remain with 26%.

Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018